Filters
| Tests names and labs | Conditions | Genes, analytes, and microbes | Methods |
|---|---|---|---|
Centogene US, LLC - The Rare Disease Company United States | 734 | 744 |
|
F5 - NGS including CNV analysis Centogene AG - the Rare Disease Company Germany | 5 | 1 |
|
Centogene AG - the Rare Disease Company Germany | 1886 | 1858 |
|
Centogene AG - the Rare Disease Company Germany | 734 | 744 |
|
Centogene AG - the Rare Disease Company Germany | 669 | 688 |
|
Centogene AG - the Rare Disease Company Germany | 110 | 112 |
|
Centogene AG - the Rare Disease Company Germany | 829 | 848 |
|
Invitae Pharmacogenomics Panel Invitae United States | 43 | 37 |
|
Stroke, Cerebral Hemorrhage, Hemiplegia, and Migraine Panel PreventionGenetics United States | 342 | 156 |
|
Invitae United States | 2 | 1 |
|
Polypharmacy Comprehensive Panel Invitae United States | 33 | 24 |
|
Intermountain Healthcare Precision Genomics Intermountain Health United States | 2 | 23 |
|
Intergen Genetic Diagnosis and Research Centre Turkey | 1 | 1 |
|
Budd-Chiari syndrome, 600880, Autosomal recessive; BDCHS (Budd-Chiari syndrome) (Prenatal) (MLPA) Intergen Genetic Diagnosis and Research Centre Turkey | 1 | 1 |
|
Intergen Genetic Diagnosis and Research Centre Turkey | 1 | 1 |
|
Budd-Chiari syndrome, 600880, Autosomal recessive; BDCHS (Budd-Chiari syndrome) (MLPA) Intergen Genetic Diagnosis and Research Centre Turkey | 1 | 1 |
|
Factor V deficiency, 227400, Autosomal recessive (Congenital factor V deficiency) (MLPA) Intergen Genetic Diagnosis and Research Centre Turkey | 1 | 1 |
|
Intergen Genetic Diagnosis and Research Centre Turkey | 1 | 1 |
|
Intergen Genetic Diagnosis and Research Centre Turkey | 1 | 1 |
|
Pregnancy loss, recurrent, susceptibility to, 1, 614389, Autosomal dominant; RPRGL1 (MLPA) Intergen Genetic Diagnosis and Research Centre Turkey | 1 | 1 |
|
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.